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Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac 
disorder, with an autosomal dominant mechanism of inheritance.1,2 
It has a prevalence of 1 in 500 within the general population, and is 
a known cause of sudden cardiac death.2,3 Recognised autosomal 
dominant mutations within sarcomere proteins are found in 55  % of 
adolescents with sporadic HCM.4 Characteristic echocardiographic 
features are well described;2 a left ventricular (LV) wall thickness ≥15 
mm not explained by loading conditions is considered diagnostic 
for HCM, but diagnostic challenges exist.5 Co-existent pathologies 
associated with increased cardiac load can make ascertainment of the 
causative pathway of LV hypertrophy difficult.6 In addition, diagnosis 
in the late disease phase can be confused by ventricular dilatation 
associated with LV wall thinning.7
AF is the most common sustained arrhythmia,8 and is associated with 
a significantly increased risk of stroke and heart failure.9 HCM has been 
associated with the development of both AF and thromboembolic 
events.5 Indeed, 48-hour ambulatory monitoring is advised as part 
of the initial HCM assessment, in part, to establish whether atrial 
tachyarrhythmias are present.5 Atrial fibrosis has been demonstrated 
in some individuals with HCM, but an atrial histology similar to the 
HCM ventricular pathology has not been demonstrated.10 Despite the 
common nature of both conditions, and their considerable overlap, 
the role of anticoagulation in this population has not been fully 
investigated. This review aims to assess the evidence surrounding the 
development of thromboembolism in patients with HCM and AF.
Hypertrophic Cardiomyopathy and the 
Development of Atrial Fibrillation
Although AF is common in patients with HCM, prevalence rates differ 
significantly between studies; prevalence has been described to be 
between 12 and 28 %.11–18 Eriksson et al. showed that AF developed in 
12 % of patients (13/105) over a mean follow-up period of 13.6 ± 8.3 
years.13 Furthermore, they found that AF was the initial disease 
presentation in 10 % of patients (10/105). This report of a retrospective 
cohort analysis does not clearly detail how AF was determined. As 
such, the authors may have underestimated the true prevalence of AF 
in this population. In a retrospective cohort (n=4,821), Guttmann et al. 
demonstrated an AF prevalence of 12.5 % at baseline.19
The reported prevalence found in cohorts evaluated at specialist 
HCM centres has been found to be significantly higher. Binder and 
colleagues reported an AF prevalence of 28 % in patients with apical 
HCM.11 This rate is supported by other registries.12,16,20 A systematic 
review examining AF in the HCM population included 7,381 patients in 
the analysis. The overall prevalence of AF in this population was 22.5 % 
(95% CI [20.1–24.8]).21 However, it should be noted that not all reports 
were included in the systematic review, including some citing lower 
prevalence levels. The authors also highlighted difficulties with the 
analysis due to heterogeneity of the study populations.
Kawasaki et al. undertook prospective 24-hour Holter monitoring 
on patients with HCM, where those with pre-existing AF had been 
excluded.14 They demonstrated that 3  % of patients were shown to 
have AF paroxysms lasting >30 seconds.
AF has been shown to be subclinical in a substantial proportion of the 
general population,22 this has led to concern that a similar proportion 
of patients with HCM and AF may be under-recognised. Robinson et 
al. demonstrated that in a cohort of 52 consecutive patients with HCM 
developing AF, 89 % had a change in symptoms with the onset of the 
arrhythmia.23 Similar numbers have been reported by other groups.17 
In a small cohort (n=44) of patients with HCM undergoing device 
implantation (implantable cardioverter defibrillator [ICD], permanent 
pacemaker, or loop recorder), in those developing de novo AF (n=16) 
88 % were asymptomatic.24 
Abstract
Hypertrophic cardiomyopathy (HCM) represents a common inherited cardiac disorder with well-known complications including stroke and 
sudden cardiac death. There is a recognised association between HCM and the development of AF. This review describes the epidemiology 
of AF within the HCM population and analyses the risk factors for the development of AF. It further discusses the outcomes associated 
with AF in this population, including the evidence in support of higher stroke risk in patients with HCM with AF compared with the general 
AF population. Finally, the evidence and recommendations for anticoagulation in this patient group are addressed.
Keywords
Hypertrophic cardiomyopathy, atrial fibrillation, stroke, anticoagulation
Disclosure: CFC has received an Academic Clinical Fellowship funded by the National Institute of Healthcare Research, and AJC has received advisory and speaker fees 
from Bayer, Boehringer Ingelheim, Daiichi Sankyo and Pfizer/BMS.
Received: 1 February 2017 Accepted: 19 April 2017 Citation: Arrhythmia & Electrophysiology Review 2017;6(2):63–8. DOI: 10.15420/aer.2017:4:2
Correspondence: A John Camm, Professor of Clinical Cardiology, Cardiac Clinical and Academic Group, St George’s, University of London, Cranmer Terrace, London, 
SW17 0RE, UK. E: jcamm@sgul.ac.uk
Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy
C Fielder Camm1 and A John Camm2,3
1. University of Oxford, Oxford; 2. St George’s, University of London; 3. Imperial College, London, UK
A R R H Y T H M I A  &  E L E C T R O P H Y S I O L O G Y  R E V I E W64
Clinical Arrhythmias Atrial Fibrillation in Hypertrophic Cardiomyopathy
Risk Factors For the Presence of Atrial 
Fibrillation in Hypertrophic Cardiomyopathy
Several risk factors for the development of AF in patients with 
HCM have been identified. N-terminal pro-brain natriuretic peptide 
(NT-proBNP) levels have been shown to positively correlate with 
the presence of AF at baseline.12 Prevalent AF was seen in 11  % 
(7 patients) in the lowest tertile of NT-proBNP levels compared 
with 36 % (22 patients) in the highest tertile. Retrospective analysis 
of a large, single-centre cohort confirmed that BNP levels are 
increased in patients with HCM and AF;25 this is in line with evidence 
supporting a significant prognostic role of NT-proBNP in predicting 
the development of AF.26,27
Several studies have reported an association between left atrial (LA) 
size and the presence of AF.28,29 Spirito et al. examined a consecutive 
cohort of 668 low-risk patients with HCM (no major sudden death risk 
factors, New York Heart Association [NYHA] class I or II and no history 
of AF).28 Over a median follow-up of 5.3 years, the development of AF 
was associated with increased baseline LA diameter with a relative 
risk of 4.65 (95  % CI [2.18–9.92]) in patients with an LA diameter 
>50  mm compared with ≤40 mm. These findings support previous 
work from additional groups showing a correlation between LA size 
and the presence of AF in patients with HCM.16–18,29–31 LA volume 
has been associated with AF in a cohort of 427 patients with HCM 
(OR 1.062, 95  % CI [1.026–1.104]).32 Tani et al. demonstrated that a 
maximum LA volume of ≥56 ml identified patients with HCM and 
paroxysmal AF with a sensitivity of 80  % and specificity of 73  %.33 
Furthermore, LA volume has been shown to identify those with 
HCM and normal pump function who are at risk of poor outcomes 
(LA volume/body surface area ≥40.4 ml/m2, sensitivity 73  % and 
specificity 88  %), including the risk of sudden cardiac death.34 LA 
enlargement is commonly seen in HCM and has been suggested to 
be a consequence of impaired diastolic function.35
McKenna et al. demonstrated right-sided involvement in 44 % of patients 
with HCM.36 However, these findings have not been confirmed, and the 
underlying mechanism and importance remains unclear. Despite this, 
Doesch et al. suggest this as an important prognostic factor for 
the development of AF in HCM.37 In a cohort of 98 patients with HCM 
(38 [39  %] with AF), cardiovascular magnetic resonance revealed 
reduced tricuspid annular plane systolic excursion and increased right 
atrial size were associated with the development of AF. However, this 
group did not directly quantify right ventricular hypertrophy.
Increasing age and worsening symptoms of congestive heart failure 
(NYHA class III or IV at diagnosis) have both been shown to be 
independently associated with the development of AF (OR 2.3, 95 % CI 
[1.4–3.7] and OR 2.8, 95 % CI [1.3–6.1], respectively).16 The prevalence 
of AF has been shown to increase with age in HCM cohorts; Losi et 
al. demonstrated an increase from 4.3 % in those <50 years of age to 
13 % in those >60 years of age.18 Importantly, this group also highlights 
a large proportion of AF cases in an otherwise young population. An 
association between AF and increased age has similarly been reported 
in other large cohorts.25
Obstructive phenotypic presentation is variable in HCM.16,38 It has 
been demonstrated in several patient cohorts that LV outflow tract 
obstruction (LVOTO) is associated with increased risk of AF, in line with 
the expected physiological outcome associated with LVOTO. Indeed, 
LVOTO has been suggested to have a role in LA remodelling due to 
increased mitral regurgitation.39
It is well recognised that the range of mutations leading to the 
development of HCM can significantly alter the resultant phenotype.40 
As such, it has been hypothesised that differential genetic mutations 
may explain some element of the heterogeneity witnessed in the 
development of AF within the HCM population. The Arg663His 
(rs371898076) mutation in the myosin heavy chain beta (MYH7) gene 
was shown to correlate with a high prevalence of AF (46  %) in a 
24-patient cohort over a 7-year follow-up period.41 Mutations in the 
angiotensin-converting enzyme (ACE) gene have also been associated 
with the development of AF in patients with HCM.42 A summary of HCM 
features associated with AF development is detailed in Figure 1.
The Role of Atrial Fibrillation in Hypertrophic 
Cardiomyopathy Outcomes
Yang et al. demonstrated that AF was a risk factor for the development 
of cardiovascular events (a composite of sudden cardiac death, 
hospitalisation for heart failure, and stroke) on univariate analysis; 
however, on multivariate analysis, it was not found to be an 
independent predictor.29 In patients undergoing surgical relief of LVOTO, 
post-operative AF was associated with increased risk of a composite 
endpoint (death, appropriate ICD discharge, sudden cardiac death 
resuscitation, stroke and admission for congestive cardiac failure; 
hazard ratio [HR] 2.12, 95 % CI [1.37–3.34]).20 AF has also been found 
to be associated with worse survival in a cohort (N=1,069) of patients 
with HCM (HR 1.44, 95 % CI [1.20–1.71]).25
Analysis undertaken in a combined cohort from Italy and the USA 
demonstrated an increased risk of HCM-related death in patients 
with comorbid AF (OR 3.7, 95 % CI [1.7–8.1]).16 In a sub-group analysis, 
those who developed AF at ≤50 years of age had an increased 
risk of HCM-related mortality and progression of symptoms (1.7- 
and 1.5-fold, respectively). Increased HCM-related mortality rates17,43 
CCF = congestive cardiac failure; HCM = hypertrophic cardiomyopathy; LA = left atrial; 
NT-proBNP = N-terminal pro-brain natriuretic peptide.
Figure 1: Key Risk Factors for the Development of Atrial 
Fibrillation in Patients with Hypertrophic Cardiomyopathy
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and symptom progression related to the development of AF17 have also 
been reported by other groups. Indeed, stroke associated with AF was 
found to be the cause of 13 % of HCM-related deaths in a consecutive 
cohort of 744 patients with HCM.44
Treatment of Atrial Fibrillation in Hypertrophic 
Cardiomyopathy
Given the association between the development of AF and significant 
outcomes in HCM, prompt treatment of AF is required. In those with 
haemodynamic instability, electrical cardioversion is recommended,5 as 
with patients without HCM who develop AF.9 There is limited evidence 
to support specific treatment regimens for rate or rhythm control 
of AF in patients with HCM. Beta-blockers, diltiazem and verapamil 
are all recommended without significant evidence to support their 
efficacy in this patient group.5,9 However, given the likelihood that AF is 
highly symptomatic in HCM, conversion to sinus rhythm is considered 
beneficial. Amiodarone has been shown to be safe for use in patients 
with HCM,45 although long-term treatment is complicated by the side-
effect profile that is common with this medication. In addition, evidence 
for efficacy in this situation is derived primarily from non-randomised 
trials and is not overwelming.16,23,46 Disopyramide, recommended as a 
second-line therapy for symptomatic LVOTO,47 can be considered for 
the treatment of AF in patients with HCM;5 however, caution is needed 
in light of the potential for enhanced atrioventricular conduction and 
associated increased ventricular rate in AF.
The use of catheter ablation in patients with HCM to prevent AF 
recurrence has been shown to be potentially beneficial in a number of 
small studies.48–50 Success rates >60  % at 1 year have been reported. 
However, Di Donna et al. demonstrated that despite such overall 
success rates, redo procedures were required in 52  % of patients and 
antiarrhythmic medication was continued in 54  %.49 These results 
are not dissimilar to those seen in the general AF population. McCready 
et al. demonstrated that HCM was an independent risk factor for AF 
recurrence following multiple procedures (HR 2.42, 95 % CI [1.06–5.55]).51
Hypertrophic Cardiomyopathy and Stroke Risk
The risk of stroke in patients with HCM is well recognised, with Furlan 
et al. demonstrating a 7  % risk of cerebrovascular events over an 
average follow-up of 5.5 years.52 Incident rates of stroke in HCM, 
irrespective of AF diagnosis, have been estimated as 2.5  %/year.30 
Compared with patients with HCM in sinus rhythm, those in AF were 
shown to have an eightfold increase in stroke risk (21 versus 2.6  %) 
in a 480-patient cohort (107 AF cases) over a follow-up period of 
12.6 ± 7.7 years; thromboembolic events in patients with AF occurred 
on average 3.5 ± 3.4 years after AF diagnosis.16 This is supported by 
data from a Japanese cohort that demonstrated a 3.9-fold increased 
risk of stroke in patients with HCM and AF (23.0 versus 5.9  % at 
5 years; p<0.01).53 High risk of stroke in the HCM population is further 
supported by additional groups.30,42,54–57 A meta-analysis of this topic 
area determined an overall annual incidence of stroke in patients with 
HCM and AF of 3.75 % (see Figure 2).21 However, despite the inclusion of 
20 studies in this area, there were only 296 cases of thromboembolism 
from a pool of 6,102 HCM cases.
In a large retrospective cohort study (n=4,921), Guttmann et al. 
demonstrated that, having excluded those with prevalent AF, 2.2 % of 
patients with HCM developed thromboembolic events (cerebrovascular 
accident [CVA], transient ischaemia attack or peripheral emboli) within 
5 years.58 In addition, in patients with AF, the presence of HCM is a 
strong independent risk factor for the presence of ischaemic stroke 
(52.6 versus 15.3 %; p<0.001).53 This increased risk is recognised in the 
Japanese Circulation Society’s HCM (2012) and AF (2013) guidelines, 
which recommend anticoagulation in all patients with HCM and AF.59,60
Stratification of Thromboembolic Risk in 
Hypertrophic Cardiomyopathy
Risk stratification for the incidence of stroke in AF has been a central 
component of guidelines issued by major cardiology societies over 
the past decade.9,60,61 In inividuals without HCM, this has included 
recognition that there is a population of individuals with AF who 
remain at low risk of stroke.9 All patients with HCM developing AF are 
considered to be at high risk of thromboembolic events. However, 
a consensus on what constitutes an increased risk of stroke in the 
HCM population has yet to be clarified. The current literature suggests 
several independent risk factors for the development of stroke in 
patients with HCM and AF (see Table 1).
LA diameter, as well as being associated with the development of AF 
itself, has also been shown to be a risk factor for thromboembolic 
outcomes.17,54,58 Notably, each 1 mm increase was shown to increase 
the risk of stroke-related death (HR 1.10, 95  % CI [1.00–1.20]).17 
Increased LA size has also been suggested as an independent risk 
factor for thromboembolic events in patients with HCM without 
diagnosed AF.54
Increasing age is a recognised risk factor for stroke both within the 
general population, and particularly those with AF.9 Increasing age has 
been shown to be associated with increased risk of thromboembolic 
events in patients with HCM.30,54,58 However, it should also be noted that 
AF has been demonstrated at significantly younger ages in patients 
with HCM, and a significant number of thromboembolic events occur in 
this younger population.30 In support of this, Olivotto et al. reported that 
the risk of stroke was higher in patients ≤50 years of age.16
The presence of congestive heart failure symptoms is recognised 
as a risk factor for cerebrovascular events in the AF population. 
Forest plot From random effect meta-analysis shows study specific incidence and pooled 
incidence of thromboembolism (TE). Source: modified from Guttmann et al., 2014.21  
HCM = hypertrophic cardiomyopathy.
Figure 2: Incidence of Thromboembolism in Patients with 
Hypertrophic Cardiomyopathy and Atrial Fibrillation
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A similar position in the HCM population is supported by Maron et 
al. who demonstrated that the presence of NYHA class III–IV was 
independently associated with increased risk of stroke.30
Using a list of pre-specified risk factors, Guttmann et al. were able to 
develop a risk model for predicting the development of thromboembolic 
events in patients with HCM.58 This model included age, presence of 
AF, previous thromboembolism, presence of congestive heart failure 
symptoms, vascular disease, LA diameter and maximal ventricular wall 
thickness. The authors described good correlation with the incidence 
of thromboembolic events. Although this model is a useful addition 
to the discussion of anticoagulation in this population, the complexity 
makes its use potentially cumbersome.
Some authors have previously advised using some elements of 
currently or previously established risk stratification tools in the general 
AF population. Benchimol Barbosa et al. found that a CHADS2 score >1 
was associated with increased risk of CVA and have advocated its use 
as part of a score for the incidence of CVA in the HCM popuatlion.62 
Inoue and colleagues, when assessing thromboembolic rates in those 
with non-valvular AF, have advocated a single point for the presence 
of HCM to the CHADS2 score;63 however, they failed to define a clear 
threshold at which point anticoagulation became necessary; instead 
assigned patients to low-, moderate- and high-risk categories. A low 
CHA2DS2-VASc score has been suggested as an appropriate marker 
for identifying little risk of thromboembolism in patients with HCM 
and AF. A CHA2DS2-VASc score ≤1 was associated with an annual 
thromboembolic incidence of 0.9  %;64 this is in line with thresholds 
of anticoagulation with non-vitamin K antagonist oral anticoagulants 
(NOACs).
However the use of traditional scores in risk stratifying stroke risk 
in HCM is not proposed in current guidance issued by the European 
Society of Cardiology (ESC) or Japanese Circulation Society (JCS).5,59 This 
position is supported by evidence showing a poor correlation between 
CHA2DS2-VASc score and the development of thromboembolism in a 
Table 1: Independent Risk Factors, in Addition to the Presence of Atrial Fibrillation, Associated with the Development 
of Stroke in Patients with Hypertrophic Cardiomyopathy
 
Citation Risk factor Outcome Strength of risk Cohort AF cases CVA/TE Follow-up
   [95 % CI] size   (years)
Olivotto et al.16 Age at development of AF ≤50 years Stroke HR 3.6 (95 % CI 480 107 23 12.6 ± 7.7 
   not given)
Maron et al.30 Age >60 years as initial evaluation Thromboembolism* RR 8.2 [3.9–21.6] 900 192 51 4.9 ± 4.3
 NYHA class III or IV at initial evaluation  RR 2.4 [1.2–5.0]    5.9 ± 5.7
Benchimol CHADS2>1 Embolic stroke OR 7.7 [2.7–22.3] 172 40 17 12.3 
Barbosa et al.62 LV outflow tract gradient >38 mmHg  OR 5.5 [1.8–16.4]
Guttmann et al.58 Prior thromboembolic event Thromboembolism* HR 3.63 [1.81–7.29] 4,817 600 172 6.0 (IQR  
       3.0–9.7)
 NYHA class III or IV  HR 2.07 [1.35–3.17]
 Increasing age (per 1 year)  HR 1.03 [1.02–1.04]
 LA diameter (per 1 mm increase)  HR 1.03 [1.01–1.05]
 Maximum wall thickness  HR 1.45 [1.12–1.88] 
 (per 1 mm increase)
Tian et al.17 LA diameter (per 1 mm increase) Stroke-related death HR 1.10 [1.00–1.20] 654 112 9 4.2 ± 2.8
Haruki et al.54 LA diameter ≥48 mm Thromboembolism* HR 2.74 [1.20–6.23] 431 0† 39 10.7 ± 7.5
 Age at HCM diagnosis (per 1 year  HR 1.03 [1.01–1.06] 
 increase)
*Composite marker of CVA, transient ischaemic attack and peripheral TE. †Sub-group analysis in patients without documented AF. CVA = cerebrovascular accident; HR = hazard ratio; LA = left 
atrial; LV = left ventricular; OR = odds ratio; RR = relative reduction; TE = thromboembolism.
Table 2: Guideline Recommendations Regarding Anticoagulation of Patients with Hypertrophic Cardiomyopathy  
and Atrial Fibrillation
 
Guideline Issuing Year Patients requiring Anticoagulation Strength of
  body  anticoagulation agent (1st line) recommendation
ESC guidelines on diagnosis and management ESC 2014 All patients with HCM and AF VKA  Class I 
of hypertrophic cardiomyopathy5
ESC guidelines for the management of AF9 ESC 2016 All patients with HCM and AF No preference between Class I 
      VKA and NOAC for HCM
Guidelines for the diagnosis and treatment ACC/AHA 2011 All patients with HCM and AF VKA  Class I 
of HCM74
AHA/ACC/HRS guidelines for the management AHA/ACC/ 2014 All patients with HCM and AF No specification of VKA Class I 
of patients with AF75 HRS   or NOAC
Guidelines for diagnosis and treatment JCS 2012 All patients with HCM and AF No specification of VKA Not stated 
of patients with HCM59    or NOAC
Guidelines for the pharmacotherapy of AF60 JCS 2013 All patients with HCM and AF No specification of VKA Class IIa 
     or NOAC
ACC = American College of Cardiology; AHA = American Heart Association; ESC = European Society of Cardiology; HCM, hypertrophic cardiomyopathy; HRS = Heart Rhythm Society;  
JCS = Japanese Circulation Society; NOAC = non-vitamin K antagonist oral anticoagulant; VKA = vitamin K antagonist.
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small sub-population of un-anticoagulated patients with HCM and AF 
(n=222).58 However, it should be noted that within this group there 
were only 21 events in total and no strong conclusions can be derived 
from this analysis.
Given the strong burden of evidence supporting a high risk of 
thromboembolism in patients with HCM who develop AF, such patients 
should be identified early. To date, no research has undertaken 
the prophylactic anticoagulation of patients with HCM and high-
risk features for the development of AF. However, this may be an 
appropriate management strategy if such a population can be 
adequately defined.
Choice of Anticoagulant in Patients with 
Hypertrophic Cardiomyopathy
There is no randomised controlled trial assessing the role of 
anticoagulation among patients with HCM. Evidence is limited to that 
from small cohort studies, which show that the use of anticoagulation 
in patients with HCM and AF reduces the risk of thromboembolic 
events. Olivotto et al., in a cohort of 107 patients with HCM and AF, 
demonstrated a reduction of stroke from 39  % (n=11) in untreated 
patients to 10  % (n=6) in those treated with warfarin (p=0.001).16 
This is in line with findings from a cohort of 200 patients with HCM 
and AF, where a reduction in the cumulative incidence of stroke was 
demonstrated with anticoagulation (31  % without anticoagulation 
[n=33] versus 18 % with warfarin [n=15]; p<0.05).30 Of note, patients on 
antiplatelet agents had no significant reduction in stroke risk, which 
is in line with findings in the general AF population.5,65 The role of 
anticoagulation is supported by other data showing a reduced risk of 
stroke when anticoagulated with warfarin (31–18 %).30
At present, no data are available from randomised controlled trials 
on the effectiveness of NOACs in reducing thromboembolic risk in 
this population. Among the four major prospective trials assessing 
the efficacy of NOACs versus warfarin in AF, patients with HCM were 
not included in the analyses.66–69 Large ‘real-world’ analyses of NOAC 
therapy have also failed to provide any specific discussion of patients 
with HCM.70,71 Noseworthy et al. examined a retrospective cohort 
of patients with HCM on anticoagulation and found no significant 
difference between NOACs and vitamin K antagonists in the rate of 
ischaemic stroke (HR 1.37, 95  % CI [0.40–4.67]) or major bleeding 
(HR 0.75, 95 % CI [0.36–1.57]).72 Furthermore, a recent post hoc subgroup 
analysis of the Randomised Evaluation of Long-term Anticoagulation 
Therapy (RE-LY) study has shown that the presence of LV hypertrophy 
determined by ECG criteria lead to decreased warfarin efficacy 
(dabigatran 150 mg versus warfarin HR 0.48, 95  % CI [0.29–0.78]).73 
Although this analysis did not examine patients with HCM directly, the 
findings do suggest they may benefit from NOAC therapy.
Given the strong evidence for their use in the AF population, NOACs 
have been recommended as second-line agents in patients with HCM 
and AF.5 However, this guidance remains unaligned between major 
guideline organisations. The American College of Cardiology (ACC), 
American Heart Association (AHA), ESC, and Heart Rhythm Society 
(HRS) uniformly recommend anticoagulation of all patients with HCM 
who develop AF (see Table 2). However, only in the most recent ESC 
guidelines discussing this patient group has the use of either vitamin K 
antagonists or NOAC anticoagulation been recommended.9
Conclusion
AF represents a common comorbid condition or complication in 
patients with HCM. As in the general population, AF is associated with 
significant morbidity from thromboembolic events and consequent 
mortality. The risk of thromboembolic events is higher than in the 
general population with AF and, although some independent risk 
factors have been identified, it is recommended that everyone with AF 
and HCM should be anticoagulated to mitigate this risk. However, the 
lack of data derived from randomised controlled trials or large-scale 
cohort studies emphasises the importance of and need for prospective 
registries with regards to the development of AF and its associated 
downstream outcomes. Given the burden of AF in the HCM population, 
and the high risk of associated thromboembolic stroke, it is now 
necessary to focus on identifying patients at high-risk of developing AF 
such that prophylactic anticoagulation can be considered. n
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